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Effect of Increased Warfarin Use on Warfarin-Related
Cerebral Hemorrhage
A Longitudinal Population-Based Study
Juha Huhtakangas, MD; Sami Tetri, MD, PhD; Seppo Juvela, MD, PhD; Pertti Saloheimo, MD, PhD;
Michaela K. Bode, MD, PhD; Matti Hillbom, MD, PhD
Background and Purpose—Warfarin use has rapidly increased with the aging of the population. We investigated the temporal
trends in the incidence and outcome of warfarin-related intracerebral hemorrhages (ICHs) in a defined population.
Methods—We identified all subjects with first-ever primary ICH during 1993 to 2008 among the population of Northern
Ostrobothnia, Finland. The number of warfarin users was obtained from the national register of prescribed medicines
kept by the Social Insurance Institution of Finland. We calculated the annual incidence of warfarin-related ICHs, 28-day
case fatality, and deaths from the primary bleed.
Results—The proportion of warfarin users among the population increased 3.6-fold from 0.68% in 1993 to 2.28% in 2008.
Of a total of 982 patients with ICH, 182 (18.5%) had warfarin-related ICH. One-year survival rate after onset of stroke
was 35.2% among warfarin users and 67.9% among nonusers. The annual incidence (P0.062) and 28-day case fatality
of warfarin-related ICHs (P0.002) decreased during the observation period. Warfarin users were older (mean
difference 6.6; 95% CI, 5.0 to 8.1; P0.001) than nonusers. Admission international normalized ratio values above the
therapeutic range (2.0 to 3.0) decreased through the observation period, suggesting improved control of anticoagulant
therapy over time.
Conclusions—The annual incidence and case fatality of warfarin-related ICHs decreased, although the proportion of
warfarin users almost quadrupled in our population. (Stroke. 2011;42:2431-2435.)
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Warfarin is used to prevent cardioembolism resultingfrom atrial fibrillation and mechanical heart valves as
well as for primary prevention and treatment of deep venous
thrombosis and pulmonary embolism. The use of warfarin has
rapidly increased with the aging of the population,1,2 and the
increase in use seems to enhance the risk for severe hemor-
rhagic complications, including intracerebral hemorrhage
(ICH).3–6 A recent study from the United States showed a
marked increase in the incidence of ICH concomitant with an
increase of oral anticoagulant use.6 Although this study
screened both hospitalized people and decedents identified by
coroners, we still lack reliable population-based data to show
the effect of increased warfarin use on morbidity and mor-
tality from ICH.
In Finland, 1400 new cases of spontaneous ICH are
recorded every year.7 The number of warfarin-related bleed-
ings has not been reported, but the use of warfarin has steeply
increased, as pointed out by a recent report.2 Therefore, we
conducted a population-based study to explore the association
between warfarin use and the occurrence of warfarin-related
primary ICH (WA-ICH) in the population of Northern Os-
trobothnia. We wanted to describe the effects of the increas-
ing use of warfarin on both mortality and morbidity from
primary ICH. We tested whether increased use of warfarin
had resulted in an increased incidence of WA-ICHs.
Methods
The study protocol was approved by the ethics committee of the
Northern Ostrobothnia Hospital District. We identified all subjects
with primary ICH associated with oral anticoagulant use from
January 1, 1993, through December 31, 2008, among the population
of Northern Ostrobothnia, Finland. The study included all patients
admitted to Oulu University Hospital, which is the only hospital
serving patients with acute stroke in the area (population 1993 to
2008, 356 026 to 389 671). ICH was verified by a brain CT scan on
admission in all cases. We excluded patients not living in the
hospital’s catchment area; those who had a brain tumor, aneurysm,
vascular malformation, hematologic malignancy, hemophilia, or
head trauma; and those who had been using an anticoagulant other
than warfarin. We also identified the subjects who had died from
ICH without being admitted to our hospital by collecting data from
death records obtained from the Causes of Death Register (Statistics
Finland). The register collects the death certificates of all decedents
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in Finland by using personal social security numbers. These data
included the use of anticoagulants by the subjects at the time of
death. Seven patients died outside of the hospital, and all of them
were on warfarin. All except 1 of these cases was verified by
autopsy. The cause of death was primary bleed if ICH was registered
as the immediate cause of death in the death certificate or autopsy report.
The annual proportions of warfarin users among all subjects living
in Northern Ostrobothnia and the whole Finnish population were
obtained from the national register of prescribed medicines kept by
the Social Insurance Institution of Finland. We calculated the annual
prevalences of warfarin use in Northern Ostrobothnia, the annual
numbers of warfarin-associated new ICH cases per 1000 warfarin
users, and the annual 28-day case fatality rates and death rates due to
primary bleeds among these subjects. We observed similar case-
fatality rates of primary ICH as has been observed in other studies
from Finland. The incidence of primary ICH (17/100 000) was
comparable to observations for the whole population of Finland.7
Information about previous diseases, blood pressure histories, and
use of anticoagulants was extracted from the hospital records. Data were
extracted from the forensic autopsy charts of those who had died on the
scene. The subjects were considered to be hypertensive if their blood
pressure readings preceding the index stroke had repeatedly exceeded
160/90 mm Hg in accordance with the World Health Organization/
International Society of Hypertension statement8 or if they were taking
antihypertensive medication. The patients were recorded as having
diabetes mellitus if they used oral hypoglycemic agents or insulin.
Cardiac disease included myocardial infarction, coronary artery disease,
heart failure, and atrial fibrillation.
The patient’s clinical condition on admission was assessed using
the Glasgow Coma Scale score.9 All CT scans (and other imaging
studies) were analyzed and the locations and volumes of hematomas
measured by experienced neuroradiologists blinded to the case
history of each patient, except for the time of surgery. Because this
project was an ongoing process, 2 different methods were used to
measure ICH volume over the years. The majority were measured
using an accurate planimetric method10–12 but a minority (a small
part of those from year 2004 on) by the ABC/2 method, which offers
reasonable approximation of hematoma volume in WA-ICH and
non-WA-ICH.13 Secondary structural abnormalities were searched
for by follow-up brain imaging (CT or MRI) 2 to 3 months after the
bleed. Angiography was performed immediately if aneurysmal
bleeding was suspected. To rule out structural abnormalities causing
the hemorrhage, a control CT was done on 58%, CT angiography on
18%, digital subtraction angiography on 18%, MR angiography on
8%, and MRI on 3% of survivors.
Categorical variables were compared by the Pearson 2 test.
Univariate association of continuous variables was tested by Spear-
man rank correlation coefficients. Each patient was followed to death
or until 1 year after ICH. Cumulative survival rates were estimated
by the Kaplan-Meier product-limit method, and the curves of the
different groups were compared by the log-rank test. Analyses of
variance and covariance were used to explore the interactions among
age, use of warfarin, and year of stroke onset. Logistic regression
analysis was used to determine ORs and 95% CIs of significance of
variables in predicting case-fatality. The following variables were
tested by the forward stepwise method: age; sex; history of hyper-
tension, cardiac disease, and diabetes; and use of warfarin. The test
for significance was based on changes in log (partial) likelihood. A
2-tailed probability value of 0.05 was considered to be statistically
significant.
Results
We identified altogether 982 subjects with first-ever primary
ICH among the population of Northern Ostrobothnia from
1993 through 2008. Of them, 182 (18.5%) were on warfarin
therapy (175 were admitted to the hospital and 7 died on the
scene), whereas 800 (none died on the scene) were not. Their
characteristics are shown in Table 1. Warfarin users were
significantly older (mean age difference, 6.6 years; 95% CI,
5.0 to 8.1; P0.001), had more frequently cardiac disease
and diabetes, and showed larger hematomas on admission
than nonusers. No significant differences were observed in
Glasgow Coma Scale scores and history of hypertension.
Indications for warfarin use among the patients with ICH
were atrial fibrillation (60%), cerebral infarction (14%),
former thromboembolism (11%), cardiac disease (6%), pros-
thetic valve (5%), and other or unknown (4%). Nine of the
subjects were on both aspirin and warfarin. Those being on
both aspirin and warfarin did not have either larger hemato-
mas on admission nor more significant hematoma growth
after admission compared with other patients.
Those not on warfarin had a significantly (P0.001) better
1-year survival rate (67.9% versus 35.2%) than those who
had been on warfarin (Figure 1). The case-fatality rates of
WA-ICHs were 54.4%, 61.1%, and 64.8% for the first 28, 90,
and 365 days, respectively. The corresponding figure for
ICHs unrelated to warfarin use were 23.4%, 27.6%, and
32.1%. The 28-day case-fatality rate of warfarin users
(54.4%) was significantly higher (P0.001) than that of
nonusers (23.4%). A marked difference between the death
rates developed already during the first week after stroke
onset. Thereafter, the curves were parallel, showing no
further increase in the death rate of warfarin users compared
with nonusers. A logistic regression analysis showed that use
of warfarin, older age, and presence of cardiac disease or
diabetes were independent predictors for 28-day case-fatality
(Table 2). Age and use of warfarin were also significant
predictors for immediate (2-day) mortality.
Crude data of warfarin use and ICHs among the general
population are shown in Table 3. The number of subjects
using warfarin increased year by year. As a result, the
prevalence of users was almost 4-fold in 2008 compared with
Table 1. Characteristics of 982 Subjects With Primary ICH
Characteristics
Warfarin
Users
(n182)
Nonusers of
Warfarin
(n800)
Total
(n982)
Men, no. (%) 102 (56.0) 426 (53.3) 528 (53.8)
Mean age, y (SD) 74.4 (8.8)* 67.9 (12.6) 69.1 (12.3)
Median GCS score
on admission‡
13 (7, 15) 14 (10, 15) 14 (10, 15)
Mean hematoma
volume (SD)
47.8 (58.0)* 29.6 (37.0) 32.9 (42.1)
Mean INR (SD) 3.1 (1.2)* 1.1 (0.2) 1.5 (1.0)
Risk factors,
no. (%)
Diabetes 45/179 (25.1)† 125/799 (15.6) 170/978 (17.4)
Cardiac
disease§
133/180 (73.9)* 251/798 (31.5) 384/978 (39.3)
Hypertension 115/178 (64.6) 500/800 (62.5) 615/978 (62.9)
GCS indicates Glasgow Coma Scale; INR, international normalized ratio; SD,
standard deviation; ICH, intracerebral hemorrhage.
*P0.001 for difference between warfarin users and control subjects.
†P0.002 for difference between warfarin users and control subjects.
‡Twenty-fifth and 75th percentiles in parentheses.
§Including previous myocardial infarction, coronary artery disease, heart
failure, and atrial fibrillation.
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1993. A similar increase occurred among the whole Finnish
population during these years (data not shown), and the
prevalence of warfarin users in Northern Ostrobothnia fol-
lowed that development. However, the number of WA-ICHs
did not increase; rather, a modest decrease was observed,
whereas the incidence of ICHs not related to warfarin use
remained constant. The annual 28-day case-fatality rates also
seemed to decrease among warfarin users, whereas it re-
mained constant among nonusers.
Figure 2 illustrates the annual increase of warfarin use in
relation to the incidence of WA-ICHs and the annual 28-day
mortality rates due to WA-ICHs. The incidence of WA-ICHs
did not follow the annual prevalence of warfarin use in Northern
Ostrobothnia. There was a negative correlation (Spearman rank
0.477; P0.062) between the annual prevalence of warfarin
use and the incidence of WA-ICHs during the observation
period and a significant (P0.041) linear-by-linear association
between the increase in the prevalence of warfarin use and the
decrease of WA-ICH incidence. There was also a significant
negative correlation between the annual 28-day mortality rates
of WA-ICHs and the annual prevalence of warfarin use (Spear-
man rank 0.779; P0.002) and a significant (P0.012)
linear-by-linear association between the increase in the preva-
lence of warfarin use and the decrease of WA-ICH mortality.
Similar findings were obtained from a comparison of deaths due
to primary bleed instead of case-fatality (Spearman rank
0.799; P0.001).
To explain the lower occurrence and improved outcome of
WA-ICHs, we explored the subjects’ age as well as the
admission hematoma volumes and international normalized
ratios (INRs) as potential confounding factors. The subjects
were older year by year (Spearman rank 0.079; P0.013), but
there was no significant difference between subjects with and
without WA-ICH. Those with ICH unrelated to warfarin also
were older over time. However, the increase in age by year
Figure 1. Survival of subjects with ICH at
the time of being on warfarin therapy
(n182) compared with those not on war-
farin (n800). There is a significant differ-
ence between the survival curves
(P0.001, log-rank test). ICH indicates
intracerebral hemorrhage.
Table 2. Adjusted Multivariate Logistic Regression Analysis
for 28-Day Case-Fatality*
Multivariate Analysis OR (95% CI) P
Use of warfarin 2.502 (1.728–3.624) 0.000
Age per y 1.028 (1.013–1.044) 0.000
Cardiac disease 1.714 (1.224–2.400) 0.002
Diabetes 1.555 (1.062–2.275) 0.023
Hypertension 0.770 (0.558–1.061) 0.110
OR indicates odds ratio; CI, confidence interval.
*Adjusted for sex.
Table 3. Use of Warfarin, WA-ICH Mortality Rate per 1000
Users and Non-WA-ICH Mortality Rate per 1000 Population
Year
Population,
No.
No. of
Users
Percentage
of Users, %
WA-ICH
Mortality
Rate*
Non-WA-ICH
Mortality
Rate†
1993 356 026 2235 0.63 2.24 0.04
1994 356 026 2876 0.81 1.04 0.03
1995 361 067 3345 0.93 3.29 0.03
1996 362 850 3741 1.03 2.14 0.03
1997 364 046 4164 1.14 0.72 0.06
1998 364 981 4450 1.22 1.80 0.02
1999 366 526 4855 1.32 2.27 0.02
2000 369 399 5295 1.43 1.51 0.03
2001 372 005 5895 1.58 0.68 0.04
2002 373 868 6195 1.66 0.81 0.02
2003 375 760 5900 1.57 0.85 0.03
2004 378 679 6291 1.66 0.48 0.03
2005 381 724 6792 1.78 1.03 0.04
2006 384 280 8021 2.09 1.00 0.03
2007 386 972 8384 2.17 0.48 0.02
2008 389 671 8886 2.28 0.68 0.04
WA-ICHs indicates warfarin-related intracerebral hemorrhages.
*WA-ICH mortality rate per 1000 users.
†Non-WA-ICH mortality rate per 1000 people.
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was slightly steeper among those with WA-ICH (P0.059).
Hematomas were slightly smaller toward the end of the obser-
vation period, but there was no difference between the groups.
INR values were dichotomized into those within the therapeutic
range (2.0 to 3.0) and those above this range. We observed fewer
INR values above the therapeutic range at the end of the
observation period compared with the early years (P0.043),
suggesting improved control of anticoagulant therapy over time
(improved coagulation monitoring). The 28-day case-fatality
rate was 61.3% among those who had INR 3.0 and 45.6%
among those with INR 3.0 (P0.051). Patients with INR 3
did not differ from other warfarin patients by age, sex, and
presence of diabetes, hypertension, or cardiac disease. There was
no significant correlation between age and INR on admission
among those being on warfarin.
Discussion
Warfarin use almost quadrupled from 1993 to 2008 among
our population. However, the incidence of WA-ICHs as well
as case-fatality among warfarin users did not increase but
rather decreased. By contrast, the annual incidence of new
cases of primary ICH among nonusers and their case-fatality
remained constant during the observation period.
Our findings contrast with those of a study from the United
States, which showed a marked increase in the incidence of
ICH related to oral anticoagulant therapy concomitant to an
increase of warfarin use among elderly people.6 The authors
speculated that their alarming observation may be due to a
disproportionate increase in warfarin use among elderly
people at high risk for bleeding. There were methodological
differences between the studies. We compared official na-
tional statistics of warfarin use (the number of subjects who
used warfarin) with the incidence of strokes among a defined
population, whereas Flaherty et al6 used counting units,
which are not equivalent to the number of warfarin users, and
the population in their study was not as completely ascer-
tained as ours. However, we believe that these small meth-
odological differences do not explain the difference in
observations.
In our population, the proportion of WA-ICHs was initially
rather high (18.5%) but tended to decrease year by year
(Figure 2). Other studies have reported lower rates (5% to
17%).6,14–16 We believe that the selection of patients for
warfarin therapy and the monitoring of warfarin treatment
were not optimal in our country during the early part of the
study period but subsequently improved. This assumption is
supported by the finding that our patients had less often INR
values above the therapeutic range at the end of the observa-
tion period compared with the early years. Subjects with INR
3.0 have greater hematoma volumes and higher mortality
rates than others.17–19 Management of warfarin treatment in
elderly patients is hampered by drug interactions and the need
for scrupulous dose adjustment to maintain the desired INR
value.20 We did not observe more expeditious arrival to the
hospital nor were hematoma volumes significantly larger
during the earlier years. However, we started to use pro-
thrombin complex concentrate and vitamin K for the reversal
of INR for patients with WA-ICH in 2004. This may have
diminished the case-fatality but does not explain the de-
creased incidence of WA-ICH over time. Neither did surgical
treatment of ICH because the number of patients operated did
not show either a trend to increase nor decrease during the
observation period. Operations were performed with similar
frequency for those with and without warfarin at onset of
stroke. Moreover, the prevention and treatment of complica-
Figure 2. Annual increase of warfarin use in relation to the incidence of WA-ICHs and the annual 28-day mortality rates due to
WA-ICHs. WA-ICHs indicates warfarin-related intracerebral hemorrhages.
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tions such as thromboembolism and cardiac problems have
advanced in the 21st century parallel to the increase of
warfarin use.
Case-fatality rates among warfarin users were 2-fold com-
pared with nonusers, the difference being mainly due to the
larger hematomas of warfarin users already on admission.
Warfarin use was a significant and independent predictor for
immediate (2-day) and 28-day case-fatality together with
advanced age. Cardiac disease and diabetes were also signif-
icant and independent predictors for 28-day case-fatality. A
history of hypertension did not predict case-fatality but seemed
to protect against death within 1 year (data not shown).
Some other studies failed to reveal a significant difference
in hematoma volume between warfarin versus WA-ICHs, but
these studies were not population-based and thus subject to
case selection.13,21,22 The crucial point in improving the
outcome of WA-ICHs is certainly the prevention of hema-
toma growth.22,23 Accordingly, all subjects with ICH should
be expedited to the nearest hospital and measures to prevent
hematoma growth should be immediately used.
There are several limitations in our study. First, the patients
who died before follow-up radiological examinations were
performed may have had undetected structural abnormalities
contributing to their stroke, because autopsies were not done
for all of these cases. Moreover, 1 of the cases who died on
the scene was not autopsied. Second, the statistics kept by the
Social Insurance Institution of Finland were not quite com-
plete for the first 2 years of the study period, which may have
caused underestimation of warfarin use. Third, it is not
known whether all those subjects reported by the Social
Insurance Institution of Finland as warfarin users had really
used the medicine for a whole year or only for a shorter
period. However, as far as we know, our study is the first
from Europe to describe associations between warfarin use
and morbidity and mortality from ICH in a defined popula-
tion over time. The strengths of the study include the reliable
radiological analysis ruling out secondary abnormalities, the
statutory registration of dead certificates in Finland, and the
population-based case ascertainment.
It has long been known that ICH associated with oral
anticoagulant use carries a high (52% to 73%) mortality risk
due to early hematoma growth.3,22 Concern about an increase
in morbidity is justified because warfarin use among elderly
people has markedly increased. Therefore, we conducted a
population-based study of this important issue. We conclude
that, despite the increasing use of warfarin, the annual risk of
users to experience a fatal ICH has not increased among the
population of Northern Ostrobothnia; rather, it has decreased.
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